Full Text Available

Note: Clicking the button above will open the full text document at the original institutional repository in a new window.

Assessment of mycolic acids as ligand for nanoencapsulated anti-tuberculosis drug targeting

Thesis (PhD)--University of Pretoria, 2010.

Saved in:
Bibliographic Details
Other Authors: Swai, H.
Format: Thesis
Published: University of Pretoria 2013
Subjects:
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1867613457435590656
access_status_str Open Access
author2 Swai, H.
author_browse Swai, H.
author_facet Swai, H.
collection Thesis
dc_rights_str_mv © 2010 University of Pretoria. All rights reserved. The copyright in this work vests in the University of Pretoria. No part of this work may be reproduced or transmitted in any form or by any means, without the prior written permission of the University of Pretoria.
description Thesis (PhD)--University of Pretoria, 2010.
format Thesis
id oai:repository.up.ac.za:2263/25552
institution University of Pretoria (South Africa)
last_indexed 2026-06-10T12:36:27.243Z
license_str Other — see source repository
provenance_str_mv Harvested via OAI-PMH from UPSpace — University of Pretoria Institutional Repository
publishDate 2013
publishDateRange 2013
publishDateSort 2013
publisher University of Pretoria
publisherStr University of Pretoria
record_format dspace
source_str UPSpace — University of Pretoria Institutional Repository
spelling oai:repository.up.ac.za:2263/25552 Assessment of mycolic acids as ligand for nanoencapsulated anti-tuberculosis drug targeting Swai, H. Verschoor, Jan Adrianus ylemmer@csir.co.za Lemmer, Yolandy Nano-encapsulated anti-tuberculosis drug M. tuberculosis UCTD Thesis (PhD)--University of Pretoria, 2010. South Africa currently has the highest incidence of TB per 100 000 people in the world. In 2007 alone 112 000 people died of TB in South Africa, of which 94 000 were co-infected with HIV. Although TB treatments exist, poor patient compliance and drug resistance are challenges to TB management programs worldwide. Here, this challenge was addressed by the development of a polymeric anti-TB nanodrug delivery system for anti-TB drugs that could enable entry, targeting and sustained release for longer periods, hence reducing the dose frequency and simultaneously improve patient compliance. The aim was to prepare functionalised polymeric nano drug delivery vehicles to target TB infected macrophage cells. Successful nano encapsulation of anti-TB drugs was achieved and uptake of the antibiotics in the cells, demonstrated. A possible targeting agent, mycolic acids (MA) from M. tuberculosis was explored. The MA incorporated into nanoparticles could possibly serve as a ligand for cholesterol-rich areas, due to the cholesteroid nature of MA and the fact that MA is attracted to cholesterol. In another targeting scenario, MA incorporated into nanoparticles may interact with the anti-mycolic acid antibodies that are anticipated to be present in higher concentrations at the infected areas. The cholesteroid nature of MA was confirmed and how it related to the fine structure of the MA. The prepared MA containing nanoparticles were shown in vitro to be taken up in macrophage cell lines, without the MA hindering the uptake of the particles. In terms of toxicity, nanoparticles with or without MA were found to be acceptable for use, although MA did affect the viability of the cells more than poly, DL, lactic-coglycolic acid particles alone in in vitro studies. This paves the way for testing MA as a ligand to target anti-TB drugs to the sites of infection in human TB patients. Biochemistry unrestricted 2013-09-06T22:25:01Z 2011-06-23 2013-09-06T22:25:01Z 2011-04-07 2010-10-23 2011-06-15 Thesis Lemmer, Y 2010, Assessment of mycolic acids as ligand for nanoencapsulated anti-tuberculosis drug targeting, PhD thesis, University of Pretoria, Pretoria, viewed yymmdd < http://hdl.handle.net/2263/25552 > D11/441/ag http://hdl.handle.net/2263/25552 http://upetd.up.ac.za/thesis/available/etd-06152011-092059/ © 2010 University of Pretoria. All rights reserved. The copyright in this work vests in the University of Pretoria. No part of this work may be reproduced or transmitted in any form or by any means, without the prior written permission of the University of Pretoria. application/pdf application/pdf application/pdf application/pdf application/pdf application/pdf application/pdf application/pdf application/pdf application/pdf University of Pretoria
spellingShingle Nano-encapsulated anti-tuberculosis drug
M. tuberculosis
UCTD
Assessment of mycolic acids as ligand for nanoencapsulated anti-tuberculosis drug targeting
title Assessment of mycolic acids as ligand for nanoencapsulated anti-tuberculosis drug targeting
title_full Assessment of mycolic acids as ligand for nanoencapsulated anti-tuberculosis drug targeting
title_fullStr Assessment of mycolic acids as ligand for nanoencapsulated anti-tuberculosis drug targeting
title_full_unstemmed Assessment of mycolic acids as ligand for nanoencapsulated anti-tuberculosis drug targeting
title_short Assessment of mycolic acids as ligand for nanoencapsulated anti-tuberculosis drug targeting
title_sort assessment of mycolic acids as ligand for nanoencapsulated anti tuberculosis drug targeting
topic Nano-encapsulated anti-tuberculosis drug
M. tuberculosis
UCTD
url http://hdl.handle.net/2263/25552
http://upetd.up.ac.za/thesis/available/etd-06152011-092059/